developing but also in highly developed countries [1] [2] [3] . Although LOS is predominantly are responsible for about 26-36% of cases [3, 4] .
The early use of broad spectrum antibiotic regimens remains the cornerstone for the treatment 1 0 7 of LOS. However, which antibiotic regimen should be used is still debatable, as relevant inclusion/exclusion criteria and outcome measures [5, 6] . As a result, most antibiotics are
prescribed off-label in neonates [7, 8] and treatment guidelines are based on expert opinion 1 1 2 rather than on evidence from randomised controlled trials (RCT) [9] . As an example of this,
we showed that 49 different antibiotic regimens were used for the empiric treatment of LOS in 111 patients across Europe [10] . In addition, there is significant variation in antibiotic, paucity of new antibiotics entering the market [13] [14] [15] .
Meropenem is a low protein-bound (2%), broad-spectrum carbapenem with activity against a 1 1 9
wide variety of Gram-positive and Gram-negative bacteria including anaerobes and extended antibiotic susceptibility, relapse-and new infection rates, short term outcome of LOS and 1 4 0 mucosal colonisation with CRGNO were also evaluated. NeoMero-1 was a randomised, open-label study conducted in 18 NICUs in Estonia, Greece, were eligible for inclusion. Culture confirmed LOS was defined as the presence of at least one known to be resistant to study antibiotics, were not expected to survive for more than three 1 5 9
months, had renal failure and/or required hemofiltration or peritoneal dialysis, were excluded. Patients were centrally randomised using a computer generated randomisation list (1:1 ratio) 1 6 3 to either meropenem or one of the two SOC regimens (ampicillin + gentamicin or cefotaxime 1 6 4 + gentamicin) chosen by each site prior to the start of the study. Patients were stratified by 1 6 5 SOC regimen and use of systemic antibiotics for LOS in the 24 hours prior to randomisation. The local Ethics Committees approved the study protocol. The informed consent was signed by parents/guardians prior to randomisation. The study was overseen by an independent data safety monitoring board and was registered in 2 4 6
EudraCT database (2011-001515-31 ) and in clinicaltrials.gov (NCT01551394). 242146) but they had no role in study design or in the analysis of data. Chiesi Farmaceutici 2 5 0 S.P.A. provided meropenem and collaborated in the study management. In total 200 (74%) patients were premature (35% with birth weight <1000 g) and only 11 had a PMA >44 weeks. In the 24 hours prior to randomisation 73% of patients had received 2 9 7
antibiotics; 24% had received meropenem with a similar frequency in both study arms ( Table   2  9  8 2). with clinical (C) and culture proven (P) LOS. (57%) in the SOC arm with no differences in species distribution between study groups 3 1 5 (Table 3) . Of all Gram-negative microorganisms a total of 46 (94%) were susceptible to meropenem, 17 3 2 0 (59%) to cefotaxime, 2 (4%) to ampicillin and 32 (65%) to gentamicin. Altogether 32/63 3 2 1 (51%) of all microorganisms in the meropenem and 32/77 (42%) in the SOC arms were 3 2 2 susceptible to the allocated antibiotics. Allocated therapy was used according to the protocol in 134 (99%) of patients in the 3 2 6 meropenem and 127 (94%) in SOC arm. In total, 65 (48%) and 67 (50%), received allocated 3 2 7 therapy alone and 69 (51%) and 58 (43%) received concomitantly glycopeptides in the 3 2 8 meropenem and SOC arms, respectively. The median duration of allocated therapy was 3 2 9 comparable in both arms ] days in the meropenem vs 7.0 [IQR 2.5-9.6] days In the FAS the primary outcome (i.e. the proportion of patients with a successful outcome at In the culture confirmed LOS population the efficacy of meropenem was greater than that of 3 4 3 SOC (Table 4) .
The main reason for failure was modification of allocated therapy, which was more frequent
in the SOC than in the meropenem arm. However, time on allocated therapy did not influence 3 4 6 on probability of survival as shown in Figure 3 . lack of clinical response (18%) and inappropriate study antibiotics (18%) were the most
common reasons in the SOC arm (Table 5) . In a posthoc analysis of the FAS population, by permitting a duration of allocated therapy between 7 and 14 days (instead of 8 to 14 days), a successful outcome was more frequent in were ignored (41% vs 37%, respectively).
The success rate was greater for infants with Gram-negative than those with Gram-positive 23%, respectively in Gram negative sepsis; these differences were not statistically significant.
The influence of vancomycin as empiric baseline therapy was tested in log-binominal model
but it did not significantly influence the primary outcome. A total of 251 patients were evaluated at Day 28 either by on-site visit (66%) or by telephone New infections or clinical relapses were seen with similar frequency in both arms (Table 6 ). N -number of patients assessed for this outcome
*-only patients with success at TOC were evaluated for new infection/relapses
The rectal swabs were available for 130, 101 and 95 patients in the meropenem and for 127, A total of 193 patients (72%) had at least one adverse event (AE). All cause AEs totalled 304
and 317, with 47 and 48 serious AEs in the meropenem and SOC arms, respectively. The AEs 3 9 1 seen in ≥ 3% of patients are listed in Table 7 . In the meropenem arm the most common AEs were anaemia, thrombocytopenia and meningitis and in the SOC arm anaemia, abdominal 3 9 3 distension and apnoea. Seizures, a recognised side effect of carbapenems, were seen in four
(3%) patients in the meropenem arm and one (<1%) in the SOC arm. Renal failure occurred
in three (2%) patients in the meropenem arm and in four (3%) patients in the SOC arm. Ten patients in the meropenem and seven in the SOC arm died with an overall mortality rate 4 0 0 of 6%. While numerical differences in mortality were seen between meropenem and SOC 4 0 1 arms in the FAS population, there were no differences in mortality in culture confirmed LOS 4 0 2 (Table 4 ). The mortality rate was 1% (1/80) in Gram-positive and 10% (6/60) in Gram-4 0 3 negative infections. All but three patients who died had a BW <1200g. We have performed the largest RCT on the efficacy of antibiotics in LOS, undertaken in a 4 0 7 population of predominantly premature, critically ill hospitalized neonates in Europe. We have shown that the mortality was low with both antibiotic regimens and the efficacy of The NeoMero1 study differed from previous studies in LOS in many ways. First, it was a 4 1 7
multicentre study including countries with low to moderate antibiotic resistance rates NeoMero1 had an ambitious primary endpoint that in addition to resolution or significant antibiotic, in contrast to more liberal or less specific endpoints in previous studies [5, 19] .
The most intriguing finding of this study, in comparison to others, was a relatively low 4 2 9
success rate in terms of the composite primary endpoint in both study arms (23% in SOC vs. just one day (from 8 to 7 days) improved the success rate from 32% to 48% in the meropenem 4 3 6
and from 23% to 27% in the SOC arms. We believe that this was due to the clinicians' 4 3 7 decision to stop antibiotics earlier than the pre-defined duration, presumably because they felt In contrast to previous studies, we did not find an association between carbapenem use and
CRGNO colonization [25] [26] [27] . Of note, our study was an RCT with strict inclusion criteria, in arm but due to very low numbers no meaningful conclusions can be drawn.
The study had a few limitations. First, it was an open label study with the risk of investigator - adds significantly to the complexity and cost of a multicenter trial and is questionable from an and more feasible study designs (e.g. pharmacokinetics/pharmacodynamics, rather than solely
clinical endpoint based designs, enabling modelling/simulation and extrapolation from studies in adults) [6, 30] . It is critical to provide efficacy data for those infected with organisms We have also shown that the LOS criteria developed by an European Medicines Agency shorter treatment duration. Meropenem did not lead to enhanced colonization with CRGNOs.
9 2
We recommend that meropenem should be reserved for seriously ill premature neonates with producing ESBL and AmpC beta-lactamases are circulating. We would like to thank all patients and their parents participating in this study. Faggion, Eva Germovsek, Genny Gottardi, Tiziana Grossele, Cristina Haass, Tatiana Munera 
